Zevra Therapeutics Inc (ZVRA) - News Archive

Zevra Therapeutics, a commercial-stage biopharmaceutical company specialized in rare diseases, has publicly announced the impending presentation of pivotal data on its drug MIPLYFFA (arimoclomol) at the International Co...

In a notable development within the biotechnology and pharmaceutical sector, all three leading proxy advisory firms, Institutional Shareholder Services (ISS), Glass Lewis, and Egan-Jones, have unanimously recommended th...

In the ever-evolving landscape of biotechnology and pharmaceuticals, the proactive approach to disease awareness and early diagnosis has never been more critical. Zevra Therapeutics Inc. a company dedicated to pioneerin...

Zevra Therapeutics Enters Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million: Strategic Moves in a Dynamic MarketCelebration, Fla. Feb. 27, 2025 – Zevra Therapeutics, Inc. (NasdaqGS: Z...

Article for the CSI MarketZevra Therapeutics: Transformational Challenges Amidst Financial Strain in Rare Disease TherapeuticsCELEBRATION, Fla. — In a striving industry defined by rapid innovation and harsh competition,...

: Niemann-Pick Disease Type C (NPC) is a rare, progressive genetic disorder characterized by the malfunction of lipid transport within cells, leading to a variety of debilitating symptoms and poor quality of life. Until...

In the ever-evolving landscape of clinical research and drug development, the spotlight is increasingly shining on therapies addressing rare sleep disorders. As the upcoming Sleep Europe 2024 conference approaches, Zevr...

The recent developments within Zevra Therapeutics mark significant milestones in the landscape of rare disease treatments. The approval of MIPLYFFA (arimoclomol) by the U.S. Food and Drug Administration (FDA) as the fir...

At the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium, Zevra Therapeutics presented new clinical efficacy and safety data regarding two investigational drugs: Arimoclomol and OLPRUVA...

Zevra Therapeutics Announces Commencement of Public Offering, Aiming to Advance Rare Disease TherapeuticsCelebration, Fla. - Zevra Therapeutics, Inc. (Nasdaq: ZVRA), a pioneering company in the field of rare disease the...

The recent favorable vote by the FDA Advisory Committee regarding Arimoclomol represents a significant milestone in the quest for effective treatments for Niemann-Pick Disease Type C (NPC). This article interprets the i...

In recent trading sessions, Zevra Therapeutics (ZVRA) experienced a significant surge, with the stock gaining 21.9% on higher-than-average trading volume. However, analysts are divided on whether this jump is a sign of...

Zevra Therapeutics Partners with Orsini for Enhanced Distribution of OLPRUVA® (Sodium Phenylbutyrate) for Urea Cycle Disorders Celebration, Fla. and Elk Grove Village, Ill., June 18, 2024 - Zevra Therapeutics, Inc. (Nas...

Zevra Therapeutics, a leading pharmaceutical company dedicated to innovative solutions for sleep disorders, proudly revealed the positive final outcomes from its Phase 2 clinical trial of KP1077 at the prestigious SLEEP...

Zevra Therapeutics Secures Up to $100 Million in New Credit Facility to Advance Rare Disease Therapeutics Celebration, Fla. - Zevra Therapeutics, a leading rare disease therapeutics company, announced today that it has...

In development-stage biopharmaceutical industry, every new drug discovery and validation stands as a potential breakthrough for patients struggling with various health concerns - often unmet medical conditions. One such...

Resubmission of the New Drug Application (NDA) for arimoclomol, an experimental therapeutic agent aimed at combating Niemann-Pick disease type C (NPC), has been announced by Zevra Therapeutics, Inc., a leading pharmaceu...